EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody

Yuki Majima, David Kryza, Mitsuaki Sanada, Jacqueline Sidi-Boumedine, Patrick Mehlen, Benjamin Gibert, Jean-Yves Blay, Fumiyoshi Okano

Journal of Cancer Research and Clinical Oncology · 2025

DOI: 10.1007/s00432-025-06236-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Yuki Majima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Toray Industries, Inc. New Frontiers Research Laboratories, Kamakura, Kanagawa, Japan. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Tumor imaging or therapy using cancer specific carriers combined with a radioisotope has huge potential. In radiopharmaceutical development, it is important to ensure target specificity and minimal binding to normal tissues for both tumor detection and treatment. In previous studies, we identified CAPRIN-1 as a cancer-specific antigen, which is widely expressed on the cell surface membrane in many types of solid cancers, and created TRK-950, a humanized monoclonal antibody raised against CAPRIN-1, followed by conducting clinical development. In this proof-of-concept study, we prepared radiolabeled form of TRK-950 and investigated their potential as tumor imaging or therapeutic agents. METHODS: An [111In]In-DOTA-TRK-950 was prepared and administered to tumor-bearing mice, and its tumor accumulation and pharmacokinetics were evaluated with SPECT/CT imaging. Next, the anti-tumor effect of a [177Lu]Lu-DOTA-TRK-950 was evaluated. Additionally, radiolabeled TRK-950-F(ab')2, an antibody fragment of TRK-950, was similarly evaluated for their potential. RESULTS: At 72 h after administration of [111In]In-DOTA-TRK-950, tumor accumulation was high at 24.8% IA/g for 4T1 and 18.9% IA/g for HT-29, both of which are CAPRIN-1-high cancer cells, while tumor accumulation remained low at 7.5% IA/g for MNNG/HOS, which are CAPRIN-1-low cancer cells. Regarding therapeutic evaluations, strong anti-tumor effects and prolonged survival were observed after administration of [177Lu]Lu-DOTA-TRK-950 to 4T1 and HT-29 tumor-bearing mice. Furthermore, these results were also observed in the 4T1 tumor-bearing model with radiolabeled TRK-950-F(ab')2, which has shorter pharmacokinetics. CONCLUSION: This study demonstrates that radiopharmaceuticals targeting CAPRIN-1, including radiolabeled TRK-950 and TRK-950-F(ab')2, have high potential as radiopharmaceuticals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnimalsHumansMiceFemaleXenograft Model Antitumor AssaysTissue DistributionMice, Inbred BALB CCell Line, TumorIndium RadioisotopesSingle Photon Emission Computed Tomography Computed TomographyMice, NudeRadioisotopes

Stichwörter der Autor:innen

CAPRIN-1CancerRadioimmunotherapyTRK-950Tumor Imaging

Substanzen

RadiopharmaceuticalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedIndium RadioisotopesRadioisotopes

Autor:innen und Institutionen

  • Toray Industries, Inc. New Frontiers Research Laboratories, Kamakura, Kanagawa, Japan.
  • Lumen, Centre Léon Bérard, Lyon, France.
  • Imthernat Plateform, LAGEPP UMR5007, Lyon, France.
  • Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS5286, Université Lyon 1, Lyon, France.
  • Centre Léon Bérard, University Claude Bernard Lyon, Unicancer, Lyon, France.
  • Toray Industries, Inc. New Frontiers Research Laboratories, Kamakura, Kanagawa, Japan. fumiyoshi.okano.y9@mail.toray.

Zitieren

APA

Majima, Y., Kryza, D., Sanada, M., Sidi-Boumedine, J., Mehlen, P., Gibert, B., Blay, J. Y., & Okano, F. (2025). Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06236-4

Vancouver

Majima Y, Kryza D, Sanada M, Sidi-Boumedine J, Mehlen P, Gibert B, et al. Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06236-4

BibTeX
@article{Majima2025,
  author = {Majima, Yuki and Kryza, David and Sanada, Mitsuaki and Sidi-Boumedine, Jacqueline and Mehlen, Patrick and Gibert, Benjamin and Blay, Jean-Yves and Okano, Fumiyoshi},
  title = {Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2025},
  doi = {10.1007/s00432-025-06236-4}
}
Kostenlos starten →